



Press release

Cantargia AB
556791-6019
9 January 2017

Cantargia's research and development to be presented at Biotech Showcase in San Francisco on 9 January 2017

Cantargia AB's ("Cantargia") CEO, Göran Forsberg, will be giving a presentation of the company at the Biotech Showcase conference in San Francisco, USA on 9 January at 4 p.m. local time. The presentation will focus on the company's CAN04 product candidate for non-small cell lung cancer and pancreatic cancer and will also include an introduction to Cantargia's new CANxx project for autoimmune/inflammatory diseases.

Biotech Showcase is an investor and partner conference which gives small and medium-sized biotech companies the opportunity to present themselves and meet investors and commercial partners within the area of biopharmaceuticals. The conference attracts investors and industry experts from across the whole world and this year the organisers expect over 3,000 visitors to the event in San Francisco, USA.

Date and time: 9-11 January 2017
Place: Hilton, Union Square, San Francisco, USA
Information: <https://ebdgroup.knect365.com/biotech-showcase/>

Video presentations and interviews available

Cantargia's presentation can be followed at: <https://event.webcasts.com/viewer/event.jsp?ei=1130602>

All presentations that are recorded on camera or broadcasted live will be available on Cantargia's website, www.cantargia.com. Göran Forsberg presented Cantargia at the Inv€stival Showcase, which was organised by Biotech and Money in collaboration with Jefferies in London on 18 November 2016. The interview that was made at the time will be available at <http://www.pharmatelevision.com/PTVGUide.aspx> from 6 January 2017 and thereafter on the company's website.

For further information, please contact

Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com
Certified Adviser: Sedermera Fondkommission

This constitutes information that Cantargia is required to publish under the EU's Market Abuse Regulation. The information was submitted for publication through the above contact person on 5 January 2017, at 8:30 a.m.

Cantargia AB (publ), reg.no. 556791-6019, is a biotech company that is developing an antibody-based cancer treatment, which aims to attack cancer cells and arrest the inflammation of the tumour. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, interleukin 1 receptor associated protein "IL1RAP", in cancer stem cells in patients with leukemia that is not found in normal stem cells in the bone marrow. In preclinical studies (in vitro and in vivo) the antibody, targeted at IL1RAP, has been shown to have two potential mechanisms of action, which are complementary. The Company has selected a product candidate, CAN04, for future studies in humans and development activities have been focused on non-small cell lung cancer and pancreatic cancer.

Cantargia is listed on Nasdaq Stockholm First North (ticker: CANTA). Sedermera Fondkommission is the company's Certified Adviser. More information about Cantargia is available at <http://www.cantargia.com>.